- Source type
- Clinical resource
- Access type
- Publisher
- Publisher
- Cedars-Sinai
- Date
- 2026-06-25
- Added
- 2026-06-30
Trust profile
VV Source Trust Matrix v1.0
VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.
82
Professional clinical guidance
- Publisher type
- Professional guidance
- Bias profile
- Moderate
This source is strongest for safety and consumer context and weaker for mechanism and trial discovery.
VV Source Fit Score 1.0
Fit by use case
Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.
- Regulatory status
- 63/100
- Context Source
- Clinical outcomes
- 78/100
- Strong Support
- Mechanism
- 63/100
- Context Source
- Safety
- 86/100
- Strong Support
- Consumer context
- 82/100
- Strong Support
- Trial discovery
- 63/100
- Context Source
Best used for
- Clinical context
- Practice guidance
Weak for
- Replacing primary evidence
Used in Viral Vitalism
Related studies
No structured study record is currently attached to this source.
Related sources
ClinicalTrials.gov: first-in-human EPI-321 study in FSHD
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 1 connection
ClinicalTrials.gov: KIO-301 ABACUS-1 trial
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 0 connections
ClinicalTrials.gov: PROPEL 3 study NCT06164951
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 1 connection
ClinicalTrials.gov: ReMIND trial
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 1 connection
ClinicalTrials.gov: Safety and Efficacy of PTH-IA
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 1 connection
UCSF Clinical Trials: NGN-401 Rett syndrome study
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 84
- Publisher
- UCSF Clinical Trials
- Access
- Publisher
- Usage
- 1 connection
